Edition:
United States

Aradigm Corp (ARDM.OQ)

ARDM.OQ on NASDAQ Stock Exchange Capital Market

1.33USD
4:00pm EDT
Change (% chg)

$-0.02 (-1.48%)
Prev Close
$1.35
Open
$1.34
Day's High
$1.39
Day's Low
$1.30
Volume
2,626
Avg. Vol
10,216
52-wk High
$7.26
52-wk Low
$1.04

Summary

Name Age Since Current Position

John Siebert

78 2018 Executive Chairman of the Board, Interim Principal Executive Officer, Acting Principal Financial Officer

Juergen Froehlich

59 2018 Chief Medical Officer

Edwin Gordon

63 2018 Director

Theresa Matkovits

51 2018 Director

Frederick Hudson

72 2014 Independent Director

Biographies

Name Description

John Siebert

Dr. John M. Siebert Ph.D. is Executive Chairman of the Board, Interim Principal Executive Officer, Acting Principal Financial Officer of the Company. Dr. Siebert is Founder and Chief Executive Officer of Compan Pharmaceuticals, Inc., a companion animal pharmaceutical company. From May 2014 to November 2015, Dr. Siebert was Chief Executive Officer of Chase Pharmaceuticals, a company conducting clinical trials in Alzheimer’s disease. From 2010 to 2014, he was a Partner and Chief Operating Officer of New Rhein Healthcare Investors, LLC, a private equity group. From May 2003 to October 2008, Dr. Siebert was the Chairman and Chief Executive Officer of CyDex, Inc., a privately held specialty pharmaceutical company. From September 1995 to April 2003, he was President and Chief Executive Officer of CIMA Labs Inc., a publicly traded drug delivery company, and from July 1995 to September 1995 he was President and Chief Operating Officer of CIMA Labs Inc. From 1992 to 1995, Dr. Siebert was Vice President, Technical Affairs at Dey Laboratories, Inc., a privately held pharmaceutical company. From 1988 to 1992, he headed R&D and Quality Control at a division of Bayer Corporation. Prior to that, Dr. Siebert was employed by E.R. Squibb & Sons, Inc., G.D. Searle & Co., Gillette and The Procter & Gamble Company. Dr. Siebert holds a B.S. in Chemistry from Illinois Benedictine University, an M.S. in Organic Chemistry from Wichita State University and a Ph.D. in Organic Chemistry from the University of Missouri. Dr. Siebert also serves on the board of directors of Supernus Pharmaceuticals, Inc., which he joined in January 2011. On the Supernus Pharmaceuticals, Inc. board of directors, Dr. Siebert is a member of the Audit Committee and the Compensation Committee.

Juergen Froehlich

Dr. Juergen Froehlich, MD is Chief Medical Officer of the Company. He has more than 20 years of pharmaceutical industry experience in preclinical, clinical and regulatory activities at Boehringer Ingelheim, Genentech, Quintiles, Bristol-Myers Squibb, Ipsen and Vertex Pharmaceuticals. While at Genentech, Dr. Froehlich directed the clinical development, submission and approval of Activase for acute ischemic stroke and the early development of Xolair for the treatment of allergic rhinitis and allergic asthma. At Bristol-Myers Squibb, Dr. Froehlich oversaw the global life cycle management for Plavix and Avapro. At Ipsen, he directed the FDA submission and approval for Somatuline for acromegaly, oversaw development Dysport for cervical dystonia as well as clinical studies and regulatory strategies for recombinant porcine factor VIII in hemophilia. Dr. Forehlich was closely involved in the commercialization of various drugs and biloogics and alliance activities with other companies. Dr. Froehlich graduated from the Medical School at Wuerzburg University in Germany. He is a Diplomate of the American Board of Clinical Pharmacology, a Fellow of the American College of Clinical Pharmacology and a Fellow of the Faculty of Pharmaceutical Medicine. He also holds a dual executive MBA degree from the Graduate School of Business Administration in Zurich, Switzerland and from the State University of New York at Albany.

Edwin Gordon

Mr. Edwin Gordon is Director of the Company. He is the founder and principal of 4C Advisors, LLC, an advisory firm rendering differentiated financing, transactional and advisory services to life sciences companies. From 2012 to 2017, Mr. Gordon served as a managing director of the Health Care Investment Banking group of Ladenburg Thalmann & Co. Inc. (“Ladenburg”), a firm providing investment banking services to life sciences and other companies and a subsidiary of Ladenburg Thalmann Financial Services Inc. From 2008 to 2012, he was a managing director and head of the Health Care Investment Banking group of Ladenburg. Throughout his tenure at Ladenburg, Mr. Gordon was a member of the firm’s Equity Commitment Committee. Previously, Mr. Gordon served as a Managing Director in the health care banking groups of Merriman Curhan Ford & Co., Punk, Ziegel & Co., L.P., Cowen & Co., and Furman Selz. Prior to his career in investment banking, Mr. Gordon served as the senior Health Care Services Equity Analyst at Morgan Stanley & Co., Tucker Anthony & Day, and Prudential Bache Securities, covering hospital management, health insurance, and physician practices management companies on behalf of those firms’ institutional equity businesses. Mr. Gordon holds a BA in economics and an MBA in finance from the University of Pittsburgh.

Theresa Matkovits

Dr. Theresa Matkovits, Ph.D. is Director of the Company. She is Chief Operating Officer of ContraVir Pharmaceuticals, Inc. (“ContraVir”). Dr. Matkovits has served as ContraVir’s Chief Operating Officer since December 2017, previous to which she served as Executive Vice President, Head of Drug Development at ContraVir from May 2015 to November 2017. From March 2013 to May 2015, Dr. Matkovits was the Research and Development Program Leader at NPS Pharmaceuticals (“NPS”), where she led the integration of two commercial assets acquired from Takeda into NPS and led NPS’s global development efforts for Natpara. From 2010 to February 2013, Dr. Matkovits was Vice President, Innovation Leader for Infectious Disease at The Medicines Company, where she led the company’s development efforts for ORBACTIVE. From 1997 to 2010, Dr. Matkovits served in various roles including Executive Director, Head of Strategic Planning and Operations for Novartis, where she fulfilled leadership roles in global development and U.S. medical affairs for the company’s general medicine portfolio. Since 2017, Dr. Matkovits has served as an independent director of BioSurplus. Dr. Matkovits earned her Ph.D. in Biochemistry and Molecular Biology from the University of Medicine and Dentistry of New Jersey and completed her undergraduate studies at Alfred University.

Frederick Hudson

Mr. Frederick M. Hudson CPA is Independent Director of the Company. He retired as a partner in charge of the health care audit practice for the Washington-Baltimore business unit of the accounting firm of KPMG, LLP on January 1, 2006 after a 37-year career with the firm. Mr. Hudson is currently a director and audit committee chair of Supernus Pharmaceuticals, Inc. and a director and compliance committee member of Maxim Health Care Services, Inc. He also has recently served in a board capacity with the Board of Financial Administration of the Catholic Archdiocese of Baltimore, with the Board of Trustees of the Maryland Historical Society, and as director and audit committee chair of Educate, Inc. He is vice-chair and finance committee chair of the Board of Directors of GBMC Healthcare, Inc. and its affiliate, Greater Baltimore Medical Center. Mr. Hudson received a B.S. in Accounting from Loyola University Maryland and is a Certified Public Accountant. We believe that Mr. Hudson’s extensive accounting and health care audit experience qualify him to serve as a member of our board of directors.

Basic Compensation

Name Fiscal Year Total

John Siebert

--

Juergen Froehlich

738,831

Edwin Gordon

--

Theresa Matkovits

--

Frederick Hudson

--
As Of  30 Dec 2015

Options Compensation